We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Anatomic Origin No Longer Basis for Cancer Therapy

By Biotechdaily staff writers
Posted on 28 Apr 2006
Traditional cancer therapies, based on different drug regimens for brain, prostate, or ovarian cancer may soon be replaced with therapies that use drugs deemed to be of highest benefit, based on the tumor's pharmacologic profile rather than anatomic origin.

Researchers at the Washington University School of Medicine (St. More...
Louis, MO, USA) compared eight different kinds of cancerous tumors and found that whether the tumor was a breast tumor or a lung tumor did not correlate with how the cancer interacted with a standard anticancer drug. They analyzed 255 samples of eight different cancers, including colon, breast, prostate, ovary, lung, brain, melanoma, and lymphoma, and measured the amounts of specific proteins known to influence the effect of irinotecan, a commonly used anticancer agent.

The protein levels that determine irinotecan's effectiveness were found to be independent of the anatomic origin of the tumor. For example, the colon tumors studied varied widely in the levels of these proteins. This same variation in protein levels held true for all the tumors types examined.

"This study is the first time the pathway for a drug's effect has been analyzed in tumors from different anatomical locations,” said Howard McLeod, Pharm.D,, director of pharmacology at the Siteman Cancer Center at Washington University. "We've shown that drug effect is independent of where the tumor came from in the body. If further studies confirm that a tumor-specific approach is better than the current anatomical emphasis, oncologists may have to stop thinking of themselves as colon cancer or breast cancer specialists and let the cancer tell them which drugs to use for each specific patient.”

The researchers found that, independent of anatomic origin, some tumors had high amounts of irinotecan's cellular target, a protein called TOP1 (topoisomerase [DNA]1), while other tumors had very little. Irinotecan would likely be ineffective in tumors with low TOP1 levels. The researchers also found that tumors varied greatly in amounts of proteins that transport irinotecan into and out of their cells and in the amounts of proteins that break down irinotecan. These variations determine how well irinotecan will work in a particular tumor.

The study is to appear in an upcoming issue of the Journal of Pathology.



Related Links:
Washington University

New
Gold Member
Aspiration System
VACUSAFE
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.